Anzeige
Mehr »
Sonntag, 07.06.2026 - Börsentäglich über 12.000 News
Breaking News: Nasdaq Quantencomputer Play mit riesigem Kurspotential!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4MU | ISIN: US87975F1049 | Ticker-Symbol:
NASDAQ
05.06.26 | 21:58
1,220 US-Dollar
+0,83 % +0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TELOMIR PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TELOMIR PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur TELOMIR PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.05.Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease 182Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical...
► Artikel lesen
20.05.Telomir Pharmaceuticals, Inc. - 8-K, Current Report5
14.05.Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
30.04.Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer273Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc....
► Artikel lesen
30.04.EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study3
TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln
24.04.Telomir completes acquisition of TELI Pharmaceuticals2
24.04.Telomir schließt Übernahme von TELI Pharmaceuticals ab und sichert sich globale Rechte an Telomir-12
24.04.Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1161Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI...
► Artikel lesen
24.04.Telomir Pharmaceuticals, Inc. - 8-K, Current Report-
01.04.Telomir seeks FDA approval for Telomir-1 to treat breast cancer19
31.03.Telomir reicht IND-Antrag für Krebsmedikamentenkandidaten ein1
31.03.Telomir submits IND application for cancer drug candidate1
31.03.Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 in Advanced and Metastatic Triple-Negative Breast Cancer218First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir...
► Artikel lesen
31.03.Telomir Pharmaceuticals beantragt FDA-Zulassung für Brustkrebs-Medikament Telomir-12
27.03.Telomir Pharmaceuticals, Inc. - 8-K, Current Report5
17.03.Telomir Pharmaceuticals, Inc. - 10-K, Annual Report4
17.02.Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models339Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)...
► Artikel lesen
17.02.Telomir Pharmaceuticals, Inc. - 8-K, Current Report3
05.02.Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging768Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic...
► Artikel lesen
05.02.Telomir Pharmaceuticals, Inc. - 8-K, Current Report3
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1